Infinity Pharmaceuticals (NASDAQ:INFI) posted its earnings results on Thursday. The biotechnology company reported ($0.16) EPS for the quarter, topping the consensus estimate of ($0.20) by $0.04, Bloomberg Earnings reports. Infinity Pharmaceuticals had a negative return on equity of 537.48% and a negative net margin of 2,999.17%. The firm had revenue of $0.36 million for the quarter, compared to analyst estimates of $0.20 million.
Shares of NASDAQ INFI traded up $0.06 during trading on Friday, reaching $0.89. The stock had a trading volume of 997,371 shares, compared to its average volume of 1,389,733. Infinity Pharmaceuticals has a fifty-two week low of $0.60 and a fifty-two week high of $1.68. The company has a current ratio of 6.27, a quick ratio of 6.27 and a debt-to-equity ratio of 0.25. The business’s 50-day moving average price is $0.89 and its 200-day moving average price is $1.03.
Several brokerages have commented on INFI. Zacks Investment Research raised Infinity Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, July 21st. Oppenheimer reiterated a “buy” rating on shares of Infinity Pharmaceuticals in a research report on Friday. Wells Fargo & Co reduced their price objective on Infinity Pharmaceuticals from $1.50 to $1.00 and set an “equal weight” rating on the stock in a research report on Tuesday, May 12th. B. Riley reduced their price objective on Infinity Pharmaceuticals from $3.50 to $2.50 and set a “buy” rating on the stock in a research report on Monday, May 18th. Finally, ValuEngine upgraded Infinity Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Monday, April 27th. Two analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. The stock has an average rating of “Buy” and an average target price of $2.17.
Infinity Pharmaceuticals, Inc, a biopharmaceutical company, develops medicines for people with cancer in the United States. Its product candidate is IPI-549, an orally administered clinical-stage immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma (PI3K-gamma), which is in Phase 1/1b clinical study.
Featured Story: What are the reasons investors use put options?
Receive News & Ratings for Infinity Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Infinity Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.